

Non-Formulary Prescription Request

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Non-Formulary Prescription Requests	May be subject to quantity limit

APPROVAL CRITERIA

The individual must meet the following criteria to receive a non-formulary product if formulary alternative(s) are available:

- I. If the requested product is a brand or generic product without an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary:
 - A. Individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; **AND**
 1. Confirmation has been provided describing the nature of the inadequate response or intolerance for each product;**OR**
 2. Confirmation has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product;
 - OR**
 - B. If the request is for a combination product for which the individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; **OR**
 - C. If the request is for a product with an available alternative dosage form for the same active ingredient and same FDA approved indication on formulary, then confirmation has been provided indicating the clinical reason why the individual is unable to take an alternative formulary dosage form; **OR**
 - D. If only one formulary product is available in the same therapeutic class, the individual has had a trial of and inadequate response or intolerance to the one formulary product for the same condition and within the same therapeutic class.
- II. Any Non-Formulary medication without formulary or dosage form alternatives may be approved based on FDA approved labeled indications or accepted compendia off-label indications (e.g. AHFS, Micromedex, NCCN, etc.).

NOTE:

If the requested product is being prescribed for an indication that is an excluded benefit by the applicable health plan (e.g., weight loss, erectile dysfunction, fertility, cosmetic, hair loss, medical foods), the non-formulary exception process will not apply.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website.
<http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Multisource Brand (MSB) Agents

Override(s)	Approval Duration
Prior Authorization	1 year

Medications - Multisource Brand (MSB) Agents
ABILIFY
ACIPHEX
ADCIRCA
ADDERALL
ADDERALL XR
AFINITOR
AFINITOR DISPERZ
AMBIEN
AMBIEN CR
AMPYRA
APTENSIO XR
AUBAGIO
BUPHENYL
CARBAGLU
CELEBREX
CELEXA
CIALIS
CLOZARIL
CONCERTA
COPAXONE
CORLANOR
CRESTOR
CYMBALTA
DAYTRANA
DESOXYN
DEXEDRINE
DEXILANT
EFFEXOR XR
ELIDEL
EMFLAZA
ENDARI
ESBRIET
EVEKEO
EXJADE

FIRAZYR
FOCALIN
FOCALIN XR
FORFIVO XL
FROVA
GEODON
GILENYA
GLEEVEC
HALCION
HALDOL DECANOATE 100
HALDOL DECANOATE 50
HETLIOZ
IMITREX
INVEGA
JADENU
JADENU SPRINKLE
KEVEYIS
KORLYM
KUVAN
LATUDA
LESCOL XL
LETAIRIS
LEXAPRO
LIPITOR
LIVALO
LOTRONEX
LUNESTA
MAXALT
MAXALT-MLT
METADATE CD
METHYLIN
MYDAYIS
NEXIUM
NEXIUM 24HR
NEXIUM 24HR CLEAR MINIS
NORTHERA
NOXAFIL
NUVIGIL
PAXIL
PAXIL CR
PREVACID
PREVACID 24HR
PREVACID SOLUTAB

PRISTIQ
PROTONIX
PROVIGIL
PROZAC
RELEXXII
RELPAX
RESTORIL
REVATIO
RISPERDAL
RISPERDAL CONSTA
RITALIN
RITALIN LA
ROZEREM
SAMSCA
SAPHRIS
SEROQUEL
SEROQUEL XR
SILENOR
SPRYCEL
SYMBYAX
SYPRINE
TARGRETIN
TECFIDERA
THIOLA
THIOLA EC
TRACLEER
TREXIMET
ULORIC
VIAGRA
VYTORIN
WELLBUTRIN SR
WELLBUTRIN XR
XELODA
XENAZINE
ZAVESCA
ZOCOR
ZOLOFT
ZYPREXA
ZYPREXA ZYDIS
ZYTIGA

APPROVAL CRITERIA

Requests for a listed Multisource Brand (MSB) agent may be approved if the following criteria are met:

- I. Requested product is a brand medication with an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary;

AND

- A. Documentation is provided that individual has had a trial and inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar that is likely due to an inactive ingredient, and the inadequate response or intolerance is not anticipated with the requested product; **AND**

1. Documentation is provided describing the nature of the inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar; **OR**
2. Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA; **AND**

- B. **ONE** of the following:

1. Documentation is provided that individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; **AND**
 - a) Documentation is provided describing the nature of the inadequate response or intolerance for each product; **OR**
 - b) Documentation is provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product; **OR**
2. If the request is for a combination product for which individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; **OR**
3. If the request is for a product with an available alternative dosage form for the same active ingredient on formulary, then the individual is unable to take an alternative formulary dosage form; **OR**
4. If only one formulary product is available, the individual has had a trial of and inadequate response or intolerance to one formulary product for the same condition and within the same therapeutic class.

Requests for all other Multisource Brand (MSB) agent may be approved if the following criteria are met:

- I. Requested product is a brand medication with an FDA approved generic therapeutic equivalent or interchangeable biosimilar available on formulary;

AND

- A. Individual has had a trial and inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar that is likely due to an

inactive ingredient, and the inadequate response or intolerance is not anticipated with the requested product; **AND**

1. Confirmation has been provided describing the nature of the inadequate response or intolerance to the generic therapeutic equivalent or interchangeable biosimilar; **OR**
2. Confirmation has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA; **AND**

B. ONE of the following:

1. Individual has had a trial and inadequate response or intolerance to at least two formulary alternative products FDA approved for the same condition and within the same therapeutic class; **AND**
 - a) Confirmation has been provided describing the nature of the inadequate response or intolerance for each product; **OR**
 - b) Confirmation has been provided that a completed FDA MedWatch Adverse Event Reporting Form has been submitted to the FDA for each product; **OR**
2. If the request is for a combination product for which individual components are available as generic and/or preferred formulary products at similar doses, then the individual has had a trial and inadequate response or intolerance to the individual components that is likely due to an inactive ingredient; **OR**
3. If the request is for a product with an available alternative dosage form for the same active ingredient on formulary, then the individual is unable to take an alternative formulary dosage form; **OR**
4. If only one formulary product is available, the individual has had a trial of and inadequate response or intolerance to one formulary product for the same condition and within the same therapeutic class.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.



PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST/STEP THERAPY EXCEPTION FORM

Contains Confidential Patient Information

Complete form and fax back accordingly:

State:

Connecticut - 844-474-3350 | Georgia - 844-512-9002 |
|Indiana - 844-521-6940 | Kentucky - 844-521-6947 | Maine - 844-474-3351 | Missouri -
844-534-9053 | Nevada - 844-534-9054 | New York - 844-474-3356 | Ohio - 844-534-9055 |
|Wisconsin - 844-534-9056 | Virginia - 844-474-3358 |

Exchange:

Connecticut - 844-474-6220 | Georgia - 844-512-9003 |
|Indiana - 844-471-7938 | Kentucky - 844-471-7939 | Maine - 844-474-6221 | Missouri -
844-471-7940 | Nevada - 844-471-7941 | New York - 844-474-6226 | Ohio - 844-471-7942 |
|Wisconsin - 844-474-3340 | Virginia - 844-474-6227 | Florida – 877-671-6721 | Maryland – 877-
671-6773 | Texas – 877-671-6775 | Washington – 855-592-0981 |

Plan Specific:

COVA - 844-474-6218

Patient Name:		Member ID#:	
<input type="checkbox"/> Standard	<input type="checkbox"/> Urgent		

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.

Note: For a list of plan services that may require prior authorization, please visit wellpoint.com/pharmacy or contact CarelonRx Pharmacy Help Desk at 1-833-296-5041

Patient Information: This must be filled out completely to ensure HIPAA compliance					
First Name:	Last Name:	MI:	Phone Number:		
Address:		City:		State:	Zip Code:
Date of Birth:	<input type="checkbox"/> Male <input type="checkbox"/> Female	Height (in/cm): _____ Weight (lb/kg): _____		Allergies:	
Patient's Authorized Representative (if applicable):			Authorized Representative Phone Number:		
Insurance Information					
Primary Insurance Name:			Patient ID Number:		
Secondary Insurance Name:			Patient ID Number:		

PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST FORM

Contains Confidential Patient Information

Patient Name:	Member ID#:
---------------	-------------

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.

Prescriber Information

First Name:	Last Name:	Specialty:	
Address:	City:	State:	Zip Code:
Requestor (if different than prescriber):	Office Contact Person:		
NPI Number (individual):	Phone Number:		
DEA Number (if required):	Fax Number (in HIPAA compliant area):		
Email Address:			

Medication / Medical and Dispensing Information

Medication Name (list all that apply):			
<input type="checkbox"/> New Therapy <input type="checkbox"/> Renewal <input type="checkbox"/> Step Therapy Exception If Renewal: Date Therapy Initiated: _____ Duration of Therapy (specific dates): _____			
<input type="checkbox"/> Copay review (provide details): _____ <input type="checkbox"/> Maine: Proactive Non-formulary request (provide start date): _____			
How did the patient receive the medication? <input type="checkbox"/> Paid under Insurance Insurance Name: _____ Prior Auth Number (if known): _____ <input type="checkbox"/> Other (explain): _____			
Dose/Strength:	Frequency:	Length of Therapy/#Refills:	Quantity:
Administration: <input type="checkbox"/> Oral/SL <input type="checkbox"/> Topical <input type="checkbox"/> Injection <input type="checkbox"/> IV <input type="checkbox"/> Other: _____			
Planned date of service (medical only):			
Administration Location: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Ambulatory Infusion Center <input type="checkbox"/> Physician's Office <input type="checkbox"/> Long Term Care <input type="checkbox"/> Home Care Agency <input type="checkbox"/> Outpatient Hospital Care <input type="checkbox"/> Other (explain): _____			

PRESCRIPTION DRUG PRIOR AUTHORIZATION REQUEST FORM

Contains Confidential Patient Information

Patient Name:	Member ID#:
---------------	-------------

Instructions: Please fill out all applicable sections on both pages completely and legibly. Attach any additional documentation that is important for the review, e.g. chart notes or lab data, to support the prior authorization request.

1. Has the patient tried any other medications for this condition?			YES (if yes, complete below)	NO
Medication/Therapy (Specify Drug Name and Dosage)	Duration of Therapy (Specify Dates)	Response/Reason for Failure/Allergy		

2. List Diagnoses:	ICD-9/ICD-10:
--------------------	---------------

3. Required clinical information - Please provide all relevant clinical information to support a prior authorization review.
--

Please provide symptoms, lab results with dates and/or justification for initial or ongoing therapy or increased dose and if patient has any contraindications for the preferred drug. Please provide any additional clinical information or comments pertinent to this request for coverage or required under state and federal laws.

Attachments

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) to arrange for the return of these documents.